{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:15:01Z","timestamp":1766171701820,"version":"3.48.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04232-8","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:22:06Z","timestamp":1766125326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model"],"prefix":"10.1007","volume":"75","author":[{"given":"Masato","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Kunieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Koshiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4232_CR1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/ni1003","volume":"4","author":"F Fallarino","year":"2003","unstructured":"Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4:1206\u20131212","journal-title":"Nat Immunol"},{"key":"4232_CR2","doi-asserted-by":"publisher","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E (2020) Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 9:1777625","journal-title":"Oncoimmunology"},{"key":"4232_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM et al (2019) Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20:1083\u20131097","journal-title":"Lancet Oncol"},{"key":"4232_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","volume":"28","author":"JE Cheong","year":"2018","unstructured":"Cheong JE, Ekkati A, Sun L (2018) A patent review of IDO1 inhibitors for cancer. Expert Opin Ther Pat 28:317\u2013330","journal-title":"Expert Opin Ther Pat"},{"issue":"13","key":"4232_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35939","volume":"131","author":"TA Yap","year":"2025","unstructured":"Yap TA, Rixe O, Baldini C, Brown-Glaberman U, Efuni S, Hong DS, Massard C, Muzaffar J, Varga A, Yilmaz E et al (2025) First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. Cancer 131(13):e35939","journal-title":"Cancer"},{"issue":"1","key":"4232_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148550","volume":"132","author":"KM Lemberg","year":"2022","unstructured":"Lemberg KM, Gori SS, Tsukamoto T, Rais R, Slusher BS (2022) Clinical development of metabolic inhibitors for oncology. J Clin Invest 132(1):e148550","journal-title":"J Clin Invest"},{"issue":"40","key":"4232_CR7","doi-asserted-by":"publisher","first-page":"16723","DOI":"10.1073\/pnas.1110814108","volume":"108","author":"J Yuan","year":"2011","unstructured":"Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108(40):16723\u201316728","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4232_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.gene.2007.04.010","volume":"396","author":"HJ Ball","year":"2007","unstructured":"Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Stadlbauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS, Hunt NH (2007) Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396:203\u2013213","journal-title":"Gene"},{"key":"4232_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2019.01.006","volume":"50","author":"CS Pai","year":"2019","unstructured":"Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J et al (2019) Clonal deletion of tumor-specific T cells by interferon-\u03b3 confers therapeutic resistance to combination immune checkpoint blockade. Immunity 50:477\u2013492","journal-title":"Immunity"},{"key":"4232_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher P, Warren S, Dennis L, D\u2019Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP (2017) Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer 5:18","journal-title":"J Immunother Cancer"},{"key":"4232_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jim.2018.09.013","volume":"463","author":"C Sharpe","year":"2018","unstructured":"Sharpe C, Davis J, Mason K, Tam C, Ritchie D, Koldej R (2018) Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia. J Immunol Methods 463:97\u2013104","journal-title":"J Immunol Methods"},{"key":"4232_CR12","volume":"9","author":"D Draper","year":"2021","unstructured":"Draper D, Lapinski P, Wise S (2021) Flow cytometry and NanoString provide a comprehensive cell- and gene-based tumor profile following checkpoint inhibition in a murine bladder cancer model. J Immunother Cancer 9:275","journal-title":"J Immunother Cancer"},{"key":"4232_CR13","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V et al (2017) IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930\u20132940","journal-title":"J Clin Invest"},{"key":"4232_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0367-1","volume":"6","author":"P Danaher","year":"2018","unstructured":"Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, Cesano A (2018) Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from the cancer genome atlas (TCGA). J Immunother Cancer 6:63","journal-title":"J Immunother Cancer"},{"key":"4232_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12859-018-2435-4","volume":"19","author":"M Foroutan","year":"2018","unstructured":"Foroutan M, Bhuva DD, Lyu R, Horan K, Cursons J, Davis MJ (2018) Single sample scoring of molecular phenotypes. BMC Bioinformatics 19:404","journal-title":"BMC Bioinformatics"},{"key":"4232_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14:7","journal-title":"BMC Bioinformatics"},{"key":"4232_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108\u2013112","journal-title":"Nature"},{"key":"4232_CR18","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.7150\/jca.31727","volume":"10","author":"Z Ye","year":"2019","unstructured":"Ye Z, Yue L, Shi J, Shao M, Wu T (2019) Role of IDO and TDO in cancers and related diseases and the therapeutic implications. J Cancer 10:2771\u20132782","journal-title":"J Cancer"},{"key":"4232_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.642285","volume":"12","author":"TD Ricketts","year":"2021","unstructured":"Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E (2021) Mechanisms of macrophage plasticity in the tumor environment: manipulating activation state to improve outcomes. Front Immunol 12:642285","journal-title":"Front Immunol"},{"key":"4232_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567","journal-title":"Nature"},{"key":"4232_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002242","volume":"9","author":"J Faget","year":"2021","unstructured":"Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N (2021) Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer 9:e002242","journal-title":"J Immunother Cancer"},{"key":"4232_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) Fc\u03b3rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28:285\u2013295","journal-title":"Cancer Cell"},{"key":"4232_CR23","unstructured":"Tokunaga, M., Ishii, T., Mie, M., and Ando, M. (2017). A therapeutic agent for a tumor comprising an IDO inhibitor administered in combination with an antibody. PCT\/JP2016\/003337. WO 2017\/010106 A1."},{"issue":"1","key":"4232_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","volume":"41","author":"AJ Muller","year":"2019","unstructured":"Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC (2019) Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol 41(1):41\u201348","journal-title":"Semin Immunopathol"},{"key":"4232_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev-cancerbio-030419-033635","volume":"4","author":"BJ Van den Eynde","year":"2020","unstructured":"Van den Eynde BJ, van Baren N, Baurain J-F (2020) Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? Annu Rev Cancer Biol 4:241\u2013256","journal-title":"Annu Rev Cancer Biol"},{"issue":"1","key":"4232_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang S, Li Y (2018) Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol 11(1):100","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04232-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:58Z","timestamp":1766170918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04232-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4232"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04232-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.S., K.K., S.K., T.I., R.O., and Y.K. are employees of Kyowa Kirin Co., Ltd. T.Y. is a founder of Metagen Inc., Metagen Therapeutics Inc., and digzyme Inc. Metagen Inc. focuses on the design and control of the gut environment for human health. Metagen Therapeutics Inc. focuses on drug discovery and development which utilizes microbiome science. All of the companies had no control over the interpretation, writing, or publication of this work. The terms of these arrangements are being managed by the Institute of Science Tokyo in accordance with its conflict of interest policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal studies were performed in accordance with the Standards for Proper Conduct of Animal Experiments at Kyowa Kirin under the approval of the company\u2019s Institutional Animal Care and Use Committee. Kyowa Kirin is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"19"}}